EntryPoint Capital’s Zentalis Pharmaceuticals ZNTL Stock Holding History
Bought
Maintained
Sold
Other funds holding ZNTL
EntryPoint Capital's ZNTL Position: Q3 2026 in Review
EntryPoint Capital opened a new position in Zentalis Pharmaceuticals (ZNTL) in Q3 2026: 14,563 shares worth $40.3K. The stake represents 0.01% of the portfolio and ranks #714 among its holdings.
128 funds tracked by Wall St. Rank hold ZNTL as of Q3 2026.
- EntryPoint Capital held 14,563 shares of Zentalis Pharmaceuticals worth $40.3K as of Q3 2026.
- Zentalis Pharmaceuticals was a new EntryPoint Capital position in Q3 2026.
- Zentalis Pharmaceuticals made up 0.01% of EntryPoint Capital's portfolio in Q3 2026, its #714 holding.
- 128 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q3 2026.
Based on EntryPoint Capital's 13F filing for Q3 2026, filed 13 Nov 2026.